"each participant will receive an IV infusion of 2 x 10^6 Cymerus MSCs/kg of body weight (up to a maximum of 200 million cells)" - on par with Cohort B in our P1 trial and significantly less than competitors - sign of confidence in the data obtained thus far
"primary objective of the trial is to assess efficacy of CYP-001 in subjects with HR-aGvHD by Overall Response Rate (ORR) at Day 28"
straight to P2 in the US (despite comments on here suggesting a P1 is still required)
"at clinical centers in a number of countries, includuding the US and Australia", even though experts have claimed that AU is a developing country in the eyes of the almighty FDA
"expected to commence enrolment by later this year" with "results expected early 2024"
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)